73 results
8-K
EX-99.1
IONS
Ionis Pharmaceuticals Inc
21 Dec 23
Other Events
8:27pm
is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment … TTR in other major organs, which progressively compromises their function. The damage from misfolded TTR protein accumulation leads to disability within
8-K
EX-99.1
IONS
Ionis Pharmaceuticals Inc
10 Jul 23
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
7:00am
protein accumulation leads to disability within five years of diagnosis and is generally fatal within a decade.
About the NEURO-TTRansform Study
8-K
EX-99.1
logbjak
24 Apr 23
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
7:00am
8-K
EX-3.1
mxkrjy4cic59158on1
29 Mar 21
Amendments to Articles of Incorporation or Bylaws
10:23am
8-K
EX-99.1
rp6v0qc j4igtpl9lxx
23 Mar 21
Other Events
12:00am
S-8
EX-99.1
xl5bit
31 Dec 20
Registration of securities for employees
4:20pm
S-8
EX-99.2
lohfy40 xwn4w733fn
31 Dec 20
Registration of securities for employees
4:20pm
SC TO-C
EX-2.1
eqrdnq2l43ufgb
31 Aug 20
Information about tender offer
7:07am
8-K
EX-2.1
y7rh191sre v7t32
31 Aug 20
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics
7:05am
S-8
EX-99.2
iokm2l ogi
10 Aug 20
Registration of securities for employees
12:00am